Maui Derm Connect Poster Presentations
On September 13, we brought together six of our top Maui Derm Connect faculty to discuss some of this year’s most interesting poster submissions to the virtual conference.
Sheila Fallon-Friedlander, MD
TO VIEW POSTERS, CLICK ON LINKS BELOW.
- Kwong: The Hidden Impact of Molluscum Contagiosum: Survey of Caregivers’ Experiences with Diagnosis and Management
- Tanghetti: A New Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Efficacy and Safety in Phase 2 and Phase 3 Clinical Trials
- Cather: Rates of Malignancies Through 5 Years of Tildrakizumab Exposure in reSURFACE 1 and reSURFACE 2
- Moore: Oral Sarecycline for Moderate to Severe Acne Vulgaris
- Pariser: Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study
- Cantrell: Efficacy and Safety of Tildrakizumab 100 mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in reSURFACE 1
Ted Rosen, MD
TO VIEW POSTERS, CLICK ON LINKS BELOW.
- Blauvelt: Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Results From Two Phase 3 Studies with 1-Year Follow-up
- Lear: Effect of concomitant common cardiovascular medications on efficacy of sonidegib 200 mg daily in patients with locally advanced basal cell carcinoma: Results of the 42-month randomized, double-blind BOLT study
- Querfeld: Concomitant Use of Steroids and Chlormethine Gel Among Patients with Mycosis Fungoides-type Cutaneous T-cell Lymphoma (MF-CTCL): A Real-World Evidence Study
Eric Simpson, MD
TO VIEW POSTERS, CLICK ON LINKS BELOW.
- Simpson: Efficacy and Safety of Baricitinib in Moderate-to-Severe Atopic Dermatitis: Results from a Randomized, Double-Blinded, Placebo-Controlled Phase 3 Clinical Trial (BREEZE-AD5)
- Simpson: Rapid and Concurrent Improvements in Signs and Symptoms of Atopic Dermatitis with Baricitinib in Phase 3 Studies
Linda Stein Gold, MD
TO VIEW POSTERS, CLICK ON LINKS BELOW.
- Bissonnette: Efficacy of tapinarof cream by body region in subjects with plaque psoriasis in a phase 2b randomized controlled study
- Del Rosso: TRIFAROTENE 50 μg/g CREAM: AN EFFECTIVE AND SAFE TREATMENT FOR MODERATE FACIAL AND TRUNCAL ACNE
- Schlessinger: Subjects are Highly Satisfied with Two Treatments of AbobotulinumtoxinA a Year: Results from a Multi-Center, Year-long, Longitudinal Study
- Gordon: BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients
- Aldredge: Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion in Females with Psoriasis and Perception of Vehicle Properties
Bruce Strober, MD, PhD
TO VIEW POSTERS, CLICK ON LINKS BELOW.
- Gordon: BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients
- Leonardi: Long-term Efficacy and Safety Profile Through 5 Years of Treatment with Ixekizumab in Patients with Moderate-to-Severe Psoriasis
- Blauvelt: Ixekizumab vs. Guselkumab: Direct Comparison of Cumulative Clinical and Quality of Life Benefits Over 24 Weeks of Treatment in Patients With Moderate-to-Severe Plaque Psoriasis
- Magnolo: Secukinumab Is Highly Efficacious and Has a Favorable Safety Profile in Pediatric Patients With Moderate-to-Severe Plaque Psoriasis
- Cather: Rates of Malignancies Through 5 Years of Tildrakizumab Exposure in reSURFACE 1 and reSURFACE 2
Matthew Zirwas, MD
TO VIEW POSTERS, CLICK ON LINKS BELOW.
- Dosik: Phase I Study to Evaluate the Potential of Tirbanibulin Ointment 1%, a Novel Treatment for Actinic Keratosis (AK), to Induce a Phototoxicity Skin Reaction in Healthy Subjects
- Rice: Quality of Life Impact and Awareness of Primary Focal Hyperhidrosis in Children and Adolescents
- Silverberg: Use of topical corticosteroids with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: results from the 32-week, Phase 3 ECZTRA 3 trial
- Silverberg: Early changes in patient-relevant endpoints in three tralokinumab pivotal Phase 3 trials (ECZTRA 1?3) in adult patients with moderate-to-severe atopic dermatitis
Administrative Office
Maui Derm
41 East Lipoa Street, Suite 21
Kihei, Hawaii 96753
Follow Us
